<code id='134745B788'></code><style id='134745B788'></style>
    • <acronym id='134745B788'></acronym>
      <center id='134745B788'><center id='134745B788'><tfoot id='134745B788'></tfoot></center><abbr id='134745B788'><dir id='134745B788'><tfoot id='134745B788'></tfoot><noframes id='134745B788'>

    • <optgroup id='134745B788'><strike id='134745B788'><sup id='134745B788'></sup></strike><code id='134745B788'></code></optgroup>
        1. <b id='134745B788'><label id='134745B788'><select id='134745B788'><dt id='134745B788'><span id='134745B788'></span></dt></select></label></b><u id='134745B788'></u>
          <i id='134745B788'><strike id='134745B788'><tt id='134745B788'><pre id='134745B788'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:comprehensive    Page View:54489
          Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

          In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

          The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks. 

          advertisement

          “Oh, crap,” Secrist said to herself.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In